stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Operating cash flow
ADMA Biologics Inc's operating cash flow for fiscal 2025 was $50.4M, down 57.5% from $118.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $140.8M. Over the past ten years it has ranged from −$112.4M (fiscal 2021) to $118.7M (fiscal 2024); the current reading is higher than 91% of that period. ADMA Biologics Inc ranks 25th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $50.4M | (57.53%) |
| FY2024 | $118.7M | 1,248.55% |
| FY2023 | $8.8M | — |
| FY2022 | −$59.5M | — |
| FY2021 | −$112.4M | — |
| FY2020 | −$102.0M | — |
| FY2019 | −$76.2M | — |
| FY2018 | −$62.7M | — |
| FY2017 | −$37.3M | — |
| FY2016 | −$18.3M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $17.4M | (41.20%) |
| Jun 2026 | $29.5M | (49.29%) |
| Mar 2026 | $58.2M | 63.44% |
| Dec 2025 | $35.6M | 168.10% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| ADMA ADMA Biologics Inc | $140.8M |
| VCEL Vericel Corporation compare | $65.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| IMNM Immunome, Inc. compare | −$208.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| VERA Vera Therapeutics, Inc. compare | −$338.7M |
| BHVN Biohaven Ltd. compare | −$472.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement